CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy

Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849 Kochenderfer, 2010, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood, 116, 4099, 10.1182/blood-2010-04-281931 Morgan, 2006, Cancer regression in patients after transfer of genetically engineered lymphocytes, Science, 314, 126, 10.1126/science.1129003 Moon, 2011, Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor, Clin Cancer Res, 17, 4719, 10.1158/1078-0432.CCR-11-0351 Robbins, 2013, Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells, Nat Med, 19, 747, 10.1038/nm.3161 Kloss, 2013, Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells, Nat Biotechnol, 31, 71, 10.1038/nbt.2459 Morsut, 2016, Engineering customized cell sensing and response behaviors using synthetic notch receptors, Cell, 164, 780, 10.1016/j.cell.2016.01.012 Roybal, 2016, Precision tumor recognition by T cells with combinatorial antigen-sensing circuits, Cell, 164, 770, 10.1016/j.cell.2016.01.011 Liu, 2015, Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice, Cancer Res, 75, 3596, 10.1158/0008-5472.CAN-15-0159 Chong, 2017, PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR, Blood, 129, 1039, 10.1182/blood-2016-09-738245 Foster, 2008, Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor, J Immunother, 31, 500, 10.1097/CJI.0b013e318177092b Liu, 2016, A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors, Cancer Res, 76, 1578, 10.1158/0008-5472.CAN-15-2524 Kerkar, 2010, Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts, Cancer Res, 70, 6725, 10.1158/0008-5472.CAN-10-0735 Hu, 2017, Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18, Cell Rep, 20, 3025, 10.1016/j.celrep.2017.09.002 Lim, 2017, The principles of engineering immune cells to treat cancer, Cell, 168, 724, 10.1016/j.cell.2017.01.016 Sadelain, 2017, Therapeutic T cell engineering, Nature, 545, 423, 10.1038/nature22395 Boice, 2016, Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells, Cell, 167, 10.1016/j.cell.2016.08.032 Urnov, 2010, Genome editing with engineered zinc finger nucleases, Nat Rev Genet, 11, 636, 10.1038/nrg2842 Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci Transl Med, 3, 10.1126/scitranslmed.3002842 Sander, 2014, CRISPR-Cas systems for editing, regulating and targeting genomes, Nat Biotechnol, 32, 347, 10.1038/nbt.2842 Tebas, 2014, Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV, N Engl J Med, 370, 901, 10.1056/NEJMoa1300662 Qasim, 2017, Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells, Sci Transl Med, 9 Cong, 2013, Multiplex genome engineering using CRISPR/Cas systems, Science, 339, 819, 10.1126/science.1231143 Haurwitz, 2010, Sequence- and structure-specific RNA processing by a CRISPR endonuclease, Science, 329, 1355, 10.1126/science.1192272 Mali, 2013, RNA-guided human genome engineering via Cas9, Science, 339, 823, 10.1126/science.1232033 Cox, 2015, Therapeutic genome editing: prospects and challenges, Nat Med, 21, 121, 10.1038/nm.3793 Okamoto, 2009, Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR, Cancer Res, 69, 9003, 10.1158/0008-5472.CAN-09-1450 Provasi, 2012, Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer, Nat Med, 18, 807, 10.1038/nm.2700 Torikai, 2012, A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR, Blood, 119, 5697, 10.1182/blood-2012-01-405365 Torikai, 2013, Toward eliminating HLA class I expression to generate universal cells from allogeneic donors, Blood, 122, 1341, 10.1182/blood-2013-03-478255 Beane, 2015, Clinical scale zinc finger nuclease-mediated gene editing of PD-1 in tumor infiltrating lymphocytes for the treatment of metastatic melanoma, Molec Therapy, 23, 1380, 10.1038/mt.2015.71 Berdien, 2014, TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer, Gene Ther, 21, 539, 10.1038/gt.2014.26 Till, 2012, CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results, Blood, 119, 3940, 10.1182/blood-2011-10-387969 Faitschuk, 2016, Chimeric antigen receptor T cells targeting Fc mu receptor selectively eliminate CLL cells while sparing healthy B cells, Blood, 128, 1711, 10.1182/blood-2016-01-692046 Smith, 2003, Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance, Oncogene, 22, 7359, 10.1038/sj.onc.1206939 Ren, 2017, Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition, Clin Cancer Res, 23, 2255, 10.1158/1078-0432.CCR-16-1300 Liu, 2017, CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells, Cell Res, 27, 154, 10.1038/cr.2016.142 Ren, 2017, A versatile system for rapid multiplex genome-edited CAR T cell generation, Oncotarget, 8, 17002, 10.18632/oncotarget.15218 Ren, 2016, Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition, Clin Cancer Res Liu, 2016, CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells, Cell Res Eyquem, 2017, Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection, Nature, 543, 113, 10.1038/nature21405 Liu, 2017, Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation, Protein Cell, 8, 514, 10.1007/s13238-017-0422-6 Gattinoni, 2011, A human memory T cell subset with stem cell-like properties, Nat Med, 17, 1290, 10.1038/nm.2446 Cheung, 2018, Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells, Nat Biotechnol, 10.1038/nbt.4047 Sabatino, 2016, Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies, Blood, 128, 519, 10.1182/blood-2015-11-683847 Gornalusse, 2017, HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells, Nat Biotechnol, 35, 765, 10.1038/nbt.3860 Aleksic, 2012, Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies, Eur J Immunol, 42, 3174, 10.1002/eji.201242606 Johnson, 2009, Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen, Blood, 114, 535, 10.1182/blood-2009-03-211714 Zhao, 2005, Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines, J Immunol, 174, 4415, 10.4049/jimmunol.174.7.4415 Willemsen, 2005, Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha, Gene Ther, 12, 140, 10.1038/sj.gt.3302388 Chinnasamy, 2011, A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer, J Immunol, 186, 685, 10.4049/jimmunol.1001775 Morgan, 2013, Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy, J Immunother, 36, 133, 10.1097/CJI.0b013e3182829903 Cameron, 2013, Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells, Sci Transl Med, 5, 10.1126/scitranslmed.3006034 Dougan, 2013, Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity, Cancer Immunol Res, 1, 99, 10.1158/2326-6066.CIR-13-0047 Thaxton, 2014, To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy, Hum Vaccines Immunotherap, 10, 3313, 10.4161/21645515.2014.973314 Jocelyn, 2016, First proposed human test of CRISPR passes initial safety review, Science, June 2018 Kleinstiver, 2016, High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects, Nature, 529, 490, 10.1038/nature16526 Slaymaker, 2016, Rationally engineered Cas9 nucleases with improved specificity, Science, 351, 84, 10.1126/science.aad5227 Ren, 2017, Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9, Protein Cell, 8, 634, 10.1007/s13238-017-0410-x